A safety study of RMC-035

Trial Profile

A safety study of RMC-035

Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs RMC 035 (Primary)
  • Indications Acute kidney injury; Preeclampsia
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jan 2018 According to an A1M Pharma AB media release, this trial is expected to last until the first quarter of 2019.
    • 14 Nov 2017 According to an A1M Pharma AB media release, company is completing the application to initiate this study.
    • 07 Nov 2017 According to an A1M Pharma AB media release, this study is planned for the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top